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Recent advances on visual cycle protein 
research and progress on clinical translation
Xin Yee Ooi1, Rujman Khan1,2, Anjalee Choudhury1, Francisco Xavier Elisarraras1,2, Jeff Grigsby3,4, Brandi Obregon1, Andrew Tsin1*
Abstract
Since the publication of our previous paper, Visual cycle proteins: Structure, function, and roles in human retinal 
disease (Tsin, et.al, JBC 293:13016, 2018) there has been significant progress on multiple topics discussed in 
this paper. In the present communication, we further explore research advances on two visual cycle proteins: 
DES1 and IRBP. In addition, we emphasize the progress of clinical translation of other visual cycle protein 
research, including the breakthrough of FDA-approved gene therapy for Leber’s congenital amaurosis, and 
additional gene therapies at different stages of clinical trials for various retinal diseases such as retinitis 
pigmentosa, diabetic retinopathy, and Stargardt’s disease. 
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Introduction
Since the publication of Visual cycle proteins: Structure, function, and roles in human retinal disease, 
there have been significant advances in research involving visual cycle proteins and the translation of 
basic science discoveries into treatment of retinal diseases, especially in terms of gene therapy. In our 
prior review article, specific visual cycle proteins, their gene mutations, and novel gene therapy treatments 
were summarized. Additional investigations, many of which involve clinical trials, have provided further 
information on the translational potential of visual cycle protein research to treat retinal diseases.
Recent Advances in Visual Cycle Proteins Research
Interphotoreceptor Retinoid Binding Protein (IRBP)
As the most abundant soluble protein in the interphotoreceptor matrix (IPM), IRBP has been linked 
as a major contributor in maintaining the IPM’s integrity [1]. However, the effects of its presence and 
absence to visual structures requires further examination. Recently, researchers demonstrated the absence 
of IRBP through CRISPR knockout irbp-/- mice and the presence of IRBP in wildtype mice. In irbp-
/- mice, the structure of the outer segments were abnormally altered, with thinning and change in space 
between the structures observed [2].  Because of the role of IRBP as a significant anti-oxidant in the 
retina, these results are consistent with others on IRBP-induced oxidative stress affecting the thickness 
of subretinal space [3,4]. 
A recent publication highlighted the significance of IRBP levels to combat detrimental effects of 
diabetes to vision. When examining vitreous and retina samples from healthy non-diabetic and diabetic 
patients, researchers discovered that there was a five-fold decrease in the expression of IRBP in patients 
with severe diabetic retinopathy (DR) in comparison to patients that did not have diabetes [5]. These 
researchers also established that there was a negative correlation between IRBP expression and severity 
of DR. Furthermore, a negative correlation between IRBP levels and levels of inflammatory cytokines 
(VEGF and IL-6) was also established. Thus, decreased IRBP levels may indicate a lack of resistance to 
the development of DR [5]. These novel findings reveal the opportunity to use IRBP as a biomarker when 
evaluating and treating DR. 
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IRBP is an important visual cycle protein to support visual 
function. In a recent study, HMG CoA reductase inhibitor (statin) 
simvastatin was found to reduce degeneration of rod photoreceptors 
and upregulate levels of IRBP under oxidative stress conditions 
induced by all-trans retinal [6]. Specifically, the study discovered 
that rod photoreceptors treated with simvastatin first had improved 
mitochondrial function when induced with oxidative stress. Further 
experiments are needed to investigate the detailed mechanism of 
simvastatin’s use in protecting photoreceptor degeneration through 
the increase of IRBP expression. 
Isomerase enzyme of the intra-retinal visual cycle -  DES1 
and RGR 
Dihydroceramide desaturase 1 (DES1) was considered the 
main enzyme involved in the photoisomerization reaction in the 
intraretinal/cone visual cycle, as it was thought to convert the retinoid 
chromophore back to cis configuration after the chromophore was 
converted to trans configuration in the photoisomerization reaction. 
It has been shown to convert all-trans-retinol to 11-cis-retinol [7]. 
However, recent studies using knockout DES1 retinas of mice 
and zebrafish show that the cone visual cycle has no interruptions, 
suggesting the DES1 does not have a significant role in supplying 
visual chromophore for cone pigment regeneration [8,9]. It has 
been reported that RGR (Retinal G-protein couple Receptor) opsin, 
working with retinol dehydrogenase 10, can provide 11-cis retinal for 
cone pigment regeneration in a light activated mechanism in Müller 
cells [10].
Clinical Translation of Visual Cycle Protein Mutations - 
Gene Therapy for Retinal Disease 
In addition to genetic research performed on mice models, 
human gene therapy has allowed for improved prognoses of previously 
irreversible blinding diseases such as retinitis pigmentosa, Leber’s 
congenital amaurosis, diabetic retinopathy, and Stargardt’s disease. 
The progression of gene therapy now exceeds the advancement of 
RPE65 gene treatment, with results promising a brighter future in 
vision.
Leber’s congenital amaurosis (LCA)
While there are several mutations of visual cycle proteins 
associated with Leber’s congenital amaurosis (LCA), LCA caused by 
mutations of RPE65 is observed in nearly 6% of cases [11]. Focus on 
this pathology mechanism has grown rapidly because of the United 
States Food and Drug Administration’s 2017 approval of Luxturna 
(voretigene neparvovec-rzyl), a form of one-time gene therapy, to treat 
RPE65 mutations in LCA patients. Functional assays can be utilized 
to decide which specific RPE65 gene mutations are best suited for 
gene therapy in different individuals [12]. In one study, investigators 
used functional assays to determine the association between variants 
of uncertain significance (VUS) and their impact on RPE65 
protein function as an indicator of gene therapy success. Measuring 
isomerase activity of RPE65 VUS using functional assays revealed 
some patients do not exhibit isomerase activity or proper protein 
function. Thus, making certain VUS unsuitable for gene therapy. 
In comparison, patients whose RPE65 VUS exhibited isomerase 
activity went on to receive successful gene therapy procedures [12]. 
Usage of functional assays allows for accurate estimation of VUS 
pathogenicity to determine gene therapy compatibility.
One of the markers of LCA is impairment of photoreceptors 
due to 11-cis-retinal deficiency and degradation of photoreceptor 
cells, often caused by proteasome stress [13]. Knockout mice 
models rpe65-/- (LCA2) and lrat -/- (LCA14) with deletion of 
M-opsins were used to determine the effects of opsin absence on 
photoreceptors. Mice with the deleted M-opsin gene experienced 
lower levels of proteasome stress and subsequent preservation of cone 
photoreceptors. Since cone opsins are found in higher quantities 
than other proteins, they have the largest impact on photoreceptor 
viability. However, investigators confirmed that cone photoreceptors 
were able to survive without cone opsins [13]. Through closer 
examination of this mechanism, there is potential in analyzing other 
options in addressing photoreceptor degeneration beyond 11-cis-
retinal deficiency compensation.  Further investigations may be 
conducted to pharmaceutically promote proteasome activity and 
photoreceptor preservation to supplement gene therapy.
The long term efficacy of gene therapy has been a looming yet 
present concern. Investigators recognized that RPE65 gene therapy 
was capable of retaining photoreceptors during primary onset 
of disease, before any degeneration of photoreceptors. However, 
gene therapy in later stages of the disease, when photoreceptor 
degeneration transpired, was substantially less effective. A group of 
researchers tested gene therapy effects at different stages of RPE65 
gene therapy using animal models [14]. After initiating gene therapy 
in mutant canines with varying severity of photoreceptor loss and 
ages, researchers found that some regions in canine ocular tissue 
showed well-preserved photoreceptor nuclei in retinal regions with 
high expression of RPE65. Interestingly, the same research group 
found retinal regions where photoreceptors were viable with no 
RPE65 expression. Researchers noted that it was not the age of 
subjects, but the progression of the disease, primarily the extent of 
photoreceptor degeneration, that may determine long-term success 
of gene therapy [14]. With the current data in canines available, 
to translate the study to humans, it is important to consider that 
retinal degeneration may still occur even if disease conditions may 
be ameliorated. 
There have also been new studies that investigate CRISPR 
gene-editing application for inherited retinal diseases. A subtype 
of LCA, LCA10, has had some recent gene editing advancements 
using in-vitro models. LCA10 involves a specific mutation in the 
ciliopathy gene CEP290 [15,16]. Most LCA10 patients have the 
IVS26 mutation, which creates an erroneous splice in an intron 
sequence and results in the non-functional CEP290 protein. A 
potential candidate for LCA-type 10 treatment is EDIT-101 [16]. 
It uses an adeno-associated virus type 5 vector to transmit S. Aureus 
Cas9 and CEP290-specific guide RNAs (gRNAs) to photoreceptor 
cells via subretinal injection. In this study, researchers recognized 
two particular gRNAs that are specific to the CEP290 gene locus, 
allowing for the gRNA to efficiently edit the mutated CEP290 in 
human cells and retinal tissue. The pairing of SaCas9 and gRNAs to 
remove the inaccurate insertion of the intron sequence is shown to 
restore the CEP290 gene for proper RNA splicing and consequent 
protein expression [16]. Other options in genetic alterations increase 
the chances of reversing this inherited retinal disease.
Retinitis pigmentosa (RP)
Previously, we indicated that retinitis pigmentosa (RP) 
presents as rod-cone dystrophy, meaning that there is a loss of rod 
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photoreceptors before cone photoreceptors. As a result, recent studies 
focused on decreasing photoreceptor loss to improve visual function. 
The use of gene therapies, using adeno-associated vectors (AAV), 
AAV2/5-hPDE6β vector to target roc cGMP phosphodiesterase 
6β are currently in phase 1 of clinical trials, with a high possibility 
to move on to the final stage of testing (phase 2) [17]. Other gene 
therapies currently in phase 1 of clinical trials are the AAV2/5-hRKp 
vector and the AAV vector RST-001 (Chop2), of which the latter 
is used to increase the photosensitivity gene to treat underlying 
conditions found in RP [17,18]. Additionally, current treatments 
under investigation include the same voretigene neparvovec-rzyl that 
was FDA-approved for LCA treatment, AAV serotype 8 (AAV8)-
sCX3CL1, and ciliary neurotrophic factor (CNTF)- secreting 
neural stem cells (NSC) that have provided potential protection 
to photoreceptor cells in RP models [17-19]. The gene therapies 
currently under clinical trial demonstrate the promise of possible 
cures for RP.
Although RPE65 mutations account for a small percentage 
of RP cases, one of the major causes of X-linked RP includes a 
mutation on the RP GTPase (RPGR) gene that induces the thinning 
of the ONL. Since this gene is not as large as other genes that affect 
RP, RPGR has been the target of current research and development 
using AAV8 [20,21]. The idea of using AAV8 to transfect a codon-
optimized RPGR coding sequence (AAV8-coRPGR) to treat RPGR-
associated RP cases is currently being tested on human subjects [21]. 
Researchers established that patients receiving a higher dosage of the 
AAV8-coRPGR treatment showed a greater retention of improved 
visual field. Considerable progress has been made in establishing an 
alternative gene therapy to correct RP-related visual impairment, but 
more testing is needed to verify this prospective treatment.
Diabetic retinopathy (DR)
Previously, we mentioned some of the challenges in treatment 
of DR. Diabetic vascular complications remain one of the leading 
causes of blindness worldwide, and, although there have been 
significant improvements with the advent of anti-VEGF injections, 
it is still unclear what factors allow for preventing disease progression. 
It has been suggested that anti-VEGF therapies provide protection 
to Müller cells thus preventing further neural degradation [22]. 
Furthermore, researchers discovered that IRBP could block 
the damaging effects of VEGF and inflammatory cytokines by 
inhibiting tyrosine phosphorylation and by blocking GLUT1 to 
halt transportation of sugar into endothelial cells like Müller cells 
[5]. With this groundbreaking data, the study demonstrated that 
restoring IRBP levels up to physiologic baseline concentrations in 
DM rat models could potentially prevent or even reverse retinal 
abnormalities like vascular permeability [5]. In another study, 
diabetes-induced oxidative stress was attributable to superoxide 
from photoreceptors in early phase in the development of diabetic 
retinopathy [23]. Nonetheless, gene therapy investigations are 
underway to better understand the dynamic pathway leading to 
retinal neovascularization and vascular hyperpermeability.
Mesenchymal stem cell therapy has also demonstrated potential 
as immunomodulatory agents in DR, illustrating neuroprotective 
effects in light- and ischemia-induced retinal degeneration of animal 
models [17]. It is thought that stem cells exhibit neuroprotection by 
secreting neurotrophic factors, which promote tissue regeneration, 
inhibit fibrosis and apoptosis, and modulate the immune system to 
reduce inflammation [24]. In particular, endothelial progenitor cells 
(EPCs) and endothelial colony forming cells (ECFCs), a subtype 
of EPCs, have displayed promising capabilities of incorporating 
themselves into host retinal tissue and preventing dysfunctional 
angiogenesis [17,25,26]. Clinical trials have reported adequate safety 
and tolerance when evaluating stem cell treatment for photoreceptor 
degenerative diseases. However, future studies are needed to enhance 
knowledge of this type of therapy and to reinforce its efficacy [24,26].
Stargardt’s disease (STGD)
Stargardt’s disease (STGD) is caused by a number of mutations 
to the ABCA4 gene [27]. Improper functioning of this transporter 
protein results in all-trans-retinaldehyde buildup, collapsing the 
visual cycle and leading to photoreceptor cell death. There is currently 
no effective therapy for the disease, but there is hope for a solution 
soon, as major progress has been in possible therapies. Direct gene 
replacement, AAV gene delivery, and lentiviral gene delivery have all 
been researched extensively, but lentiviral has been demonstrated to 
be most effective due to its capacity to securely carry ABCA4 cDNA, 
which is nearly 7kb [28]. There are also non-viral gene therapies, 
mainly through nanoparticles, being researched.
Phase I/IIa clinical trials are being completed with lentiviral 
vectors and compacted DNA nanoparticules to treat patients 
[29]. A very recent publication using (1-aminoethyl)iminobis[N-
(oleoylcysteinyl-1-amino-ethyl)propio-namide (ECO) to transduce 
wild-type ABCA4 into mice shows great promise [30]. ECO is 
a pH-sensitive amino lipid that forms stable nanoparticles with 
nucleic acids; with pABCA4 plasmids, ECO easily forms stable 
nanoparticles. The ECO/pABCA4 nanoparticles self-assemble and 
have in vitro transfection efficiency. This system needs to be further 
modified to increase efficiency and enhance gene expression, but if 
successful, a therapy with little to no side-effects due to the nature 
of the nanoparticles could be used to treat STGD [30]. As ABCA4 
malfunction applies to STGD, types of RP, cone-rod dystrophy, and 
age-related macular degeneration, gene therapies to deliver functional 
ABCA4 may also be useful in treating several other retinal diseases. 
Conclusion
The publication of Visual cycle proteins: Structure, function, and 
roles in human retinal disease highlighted the need to further explore 
pathways in the visual cycle and related clinical investigations 
including gene therapy. Recent discoveries about the role of IRBP, 
DES1, and RGR have further clarified the understanding of visual 
cycle pathway. Clinical trials are presently ongoing to test the 
effectiveness of gene therapy treatments. As additional research is 
conducted, our understanding of blinding diseases will be continual 
to expand leading to the likelihood of future breakthroughs to novel 
treatment of many ocular ailments. 
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